OTLKHealthcare · BiotechnologyThe 4 Wall Street analysts covering Outlook Therapeutics, Inc. hold a median 12-month price target of $4 — +567.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Outlook Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (72): Smaller than most of the companies we track.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OTLK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +567.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | Ascendiant Capital | Maintains | Buy | $10 → $11 |
| 14 Aug 2026 | BTIG | Reiterates | Buy | $4.00 |
| 14 Aug 2026 | BTIG | Reiterates | Buy | — |
| 27 July 2026 | BTIG | Upgrade | Buy | $4.00 |
| 27 July 2026 | BTIG | Upgrade | Buy | — |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Neutral | $0.50 → $1.60 |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 11 June 2026 | Ascendiant Capital | Maintains | Buy | $6.00 → $10 |
| 11 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 18 May 2026 | BTIG | Downgrade | Neutral | — |
| 11 Mar 2026 | Ascendiant Capital | Maintains | Buy | — |
| 18 Feb 2026 | Chardan Capital | Maintains | Neutral | — |
| 18 Feb 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 Jan 2026 | Chardan Capital | Maintains | Neutral | — |
| 2 Jan 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 29 Aug 2025 | Guggenheim | Downgrade | Neutral | — |
| 29 Aug 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OTLK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Outlook Therapeutics, Inc. returned −51.3% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 99% of US stocks
Cheaper than 97% of US stocks
Cheaper than 75% of US stocks
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 57% of US stocks
Higher than 98% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Outlook Therapeutics, Inc. has a market value of $137.3M and an enterprise value of $150.8M.
Revenue in the twelve months to 30 June 2026: −$1.2M. The latest quarter shrank 99.4% year on year.
Net income over the same four quarters: −$61.1M, a 5253.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$56.2M.
Trailing P/E: 0.6×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Outlook Therapeutics, Inc. employs 17 people — −$68K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| OTLKOutlook Therapeutics, Inc. | $137.3M | 5 |
| VYGRVoyager Therapeutics, Inc. | $141.3M | 76 |
| RNAAtrium Therapeutics, Inc. | $141.4M | 5 |
| ARMPArmata Pharmaceuticals, Inc. | $141.4M | 74 |
| AVXLAnavex Life Sciences Corp. | $142.7M | 24 |
| SPRBSpruce Biosciences, Inc. | $130.9M | 28 |
| TLSATiziana Life Sciences Ltd. (Bermuda) | $145.0M | 18 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Outlook Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Outlook Therapeutics named Greg DiPasquale chief commercial officer. The company said he will lead U.S. commercialization of LYTENAVA and has helped launch BEOVU, EYLEA and EYLEA HD.
Why it matters — The appointment puts an experienced retina commercial leader in charge of U.S. commercialization of LYTENAVA.
Outlook Therapeutics featured new CFO Kevin Lundquist in a virtual investor discussion about his decision to join the company and its path forward following FDA approval of LYTENAVA™.
Why it matters — The discussion offers OTLK watchers insight into the new CFO’s perspective on the company’s next chapter after the LYTENAVA approval.
Outlook Therapeutics has submitted an application to CMS for a permanent, product-specific HCPCS Level II J-code for LYTENAVA (bevacizumab-vikg). The company states it remains on track for a U.S. commercial launch of LYTENAVA before year-end 2026.
Why it matters — A permanent J-code is an important step in supporting reimbursement for LYTENAVA ahead of its planned U.S. commercial launch.
Otsuka and Ionis Pharmaceuticals announced positive topline results from the Phase 3 FUSION trial of ulefnersen, an investigational RNA-targeted medicine for people with FUS-ALS, a genetic subtype of amyotrophic lateral sclerosis. The study met its primary endpoint.
Why it matters — This news concerns Otsuka and Ionis, not Outlook Therapeutics, so it has no direct bearing on OTLK operations or outlook.
Outlook Therapeutics announced that a fireside chat featuring CEO Bob Jahr, conducted at the H.C. Wainwright conference, is now available on-demand. The conversation was hosted by an H.C. Wainwright managing director and senior biotechnology equity research analyst.
Why it matters — OTLK watchers can access the executive discussion for insight into the company's positioning as presented at a major investment conference.
The 4 Wall Street analysts covering Outlook Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1.6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Outlook Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outlook Therapeutics, Inc. 5 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Outlook Therapeutics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +567.9% from the last close, and Ticker Nerd's factor model ranks Outlook Therapeutics, Inc. 5 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Outlook Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OTLK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $11 over the next 12 months.
Outlook Therapeutics, Inc. returned -51.3% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology and retinal diseases.
The most recent item we track (GlobeNewsWire, 9 Oct 2026): "Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer". Outlook Therapeutics named Greg DiPasquale chief commercial officer. The company said he will lead U.S. commercialization of LYTENAVA and has helped launch BEOVU, EYLEA and EYLEA HD.
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology and retinal diseases. The company develops and commercializes LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab designed for use in retinal indications such as wet age-related macular degeneration. Its product work centers on ONS-5010, a monoclonal antibody candidate intended to address unmet needs in the treatment of retinal vascular disorders. Outlook Therapeutics operates in the specialty eye-care segment of the pharmaceutical market, where biologic therapies are used to support vision-related conditions affecting the retina. The company’s current business is built around advancing and commercializing this ophthalmic anti-VEGF therapy across regulated markets for patients with serious retinal diseases.
CEO Mr. Robert Charles Jahr · 17 employees · United States · https://outlooktherapeutics.com
